Tags : RRMS

EMD Serono’s Mavenclad (Cladribine) Receives FDA’s Approval for RRMS and

Vartika Singh March 29, 2019

Shots: The approval is based on P-III CLARITY study assessing Mavenclad vs PBO in 1,976 patients with RRMS and SPMS in adults P-III CLARITY study results: 58% reduction in the […]readmore

Tags : RRMS

EMD Serono’s Mavenclad (Cladribine) Receives FDA’s Approval for RRMS and

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : RRMS

EMD Serono’s Mavenclad (Cladribine) Receives FDA’s Approval for RRMS and

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company